Advanced

Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study

Alikhan, R; Cohen, AT; Combe, S; Samama, MM; Desjardins, L; Eldor, A; Janbon, C; Leizorovicz, A; Olsson, Carl-Gustav LU and Turpie, AGG (2003) In Blood Coagulation and Fibrinolysis 14(4). p.341-346
Abstract
The Medical Patients with Enoxaparin (MEDENOX) trial was a randomized, placebo-controlled study that defined the risk of venous thromboembolism (VTE) in acutely ill, immobilized, general medical patients and the efficacy of the low-molecular-weight heparin, enoxaparin, in preventing thrombosis. We performed a post-hoc analysis to evaluate the effect of 40 mg enoxaparin once daily on MEDENOX patient outcome in different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder and inflammatory bowel disease) and pre-defined risk factors (chronic heart and chronic respiratory failure, age, immobility, previous VTE and cancer). The primary outcome was the occurrence of documented VTE between days 1 and... (More)
The Medical Patients with Enoxaparin (MEDENOX) trial was a randomized, placebo-controlled study that defined the risk of venous thromboembolism (VTE) in acutely ill, immobilized, general medical patients and the efficacy of the low-molecular-weight heparin, enoxaparin, in preventing thrombosis. We performed a post-hoc analysis to evaluate the effect of 40 mg enoxaparin once daily on MEDENOX patient outcome in different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder and inflammatory bowel disease) and pre-defined risk factors (chronic heart and chronic respiratory failure, age, immobility, previous VTE and cancer). The primary outcome was the occurrence of documented VTE between days 1 and 14. The relative risk reduction [95% confidence intervals (CI)] for VTE comparing 40 mg enoxaparin with placebo in the subgroups were: acute heart failure, 0.29 (95% CI, 0.10-0.84); acute respiratory failure, 0.25 (95% CI, 0.10-0.65); acute infectious disease, 0.28 (95% CI, 0.09-0.81); and acute rheumatic disorder, 0.48 (95% CI, 0.11-2.16). The relative risk reduction for VTE in the pre-defined risk factor subgroups were: chronic heart failure, 0.26 (95% Cl, 0.08-0.92); chronic respiratory failure, 0.26 (95% CI, 0.10-0.68); age, 0.22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95% CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients. (C) 2003 Lippincott Williams Wilkins. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
venous thromboembolism, thromboprophylaxis, low-molecular-weight heparin, enoxaparin, safety, risk factor, subgroup, acutely ill medical patient, efficacy
in
Blood Coagulation and Fibrinolysis
volume
14
issue
4
pages
341 - 346
publisher
Lippincott Williams and Wilkins
external identifiers
  • wos:000183425300004
  • pmid:12945875
  • scopus:0037495140
ISSN
1473-5733
DOI
10.1097/01.mbc.0000061310.06975.8e
language
English
LU publication?
yes
id
e4b653eb-a74e-4ab2-90a2-44bb8f7c55ba (old id 309407)
alternative location
http://www.bloodcoagulation.com/
date added to LUP
2007-08-22 08:57:38
date last changed
2018-02-18 03:38:17
@article{e4b653eb-a74e-4ab2-90a2-44bb8f7c55ba,
  abstract     = {The Medical Patients with Enoxaparin (MEDENOX) trial was a randomized, placebo-controlled study that defined the risk of venous thromboembolism (VTE) in acutely ill, immobilized, general medical patients and the efficacy of the low-molecular-weight heparin, enoxaparin, in preventing thrombosis. We performed a post-hoc analysis to evaluate the effect of 40 mg enoxaparin once daily on MEDENOX patient outcome in different types of acute medical illness (heart failure, respiratory failure, infection, rheumatic disorder and inflammatory bowel disease) and pre-defined risk factors (chronic heart and chronic respiratory failure, age, immobility, previous VTE and cancer). The primary outcome was the occurrence of documented VTE between days 1 and 14. The relative risk reduction [95% confidence intervals (CI)] for VTE comparing 40 mg enoxaparin with placebo in the subgroups were: acute heart failure, 0.29 (95% CI, 0.10-0.84); acute respiratory failure, 0.25 (95% CI, 0.10-0.65); acute infectious disease, 0.28 (95% CI, 0.09-0.81); and acute rheumatic disorder, 0.48 (95% CI, 0.11-2.16). The relative risk reduction for VTE in the pre-defined risk factor subgroups were: chronic heart failure, 0.26 (95% Cl, 0.08-0.92); chronic respiratory failure, 0.26 (95% CI, 0.10-0.68); age, 0.22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95% CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients. (C) 2003 Lippincott Williams Wilkins.},
  author       = {Alikhan, R and Cohen, AT and Combe, S and Samama, MM and Desjardins, L and Eldor, A and Janbon, C and Leizorovicz, A and Olsson, Carl-Gustav and Turpie, AGG},
  issn         = {1473-5733},
  keyword      = {venous thromboembolism,thromboprophylaxis,low-molecular-weight heparin,enoxaparin,safety,risk factor,subgroup,acutely ill medical patient,efficacy},
  language     = {eng},
  number       = {4},
  pages        = {341--346},
  publisher    = {Lippincott Williams and Wilkins},
  series       = {Blood Coagulation and Fibrinolysis},
  title        = {Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study},
  url          = {http://dx.doi.org/10.1097/01.mbc.0000061310.06975.8e},
  volume       = {14},
  year         = {2003},
}